Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**89Zr-DFOPODSDAR2SC16-MB1** is a radiolabeled biologic tracer designed for use in positron emission tomography (PET) imaging, where the monoclonal antibody or binding scaffold “DFOPODSDAR2SC16-MB1” is conjugated with the radionuclide zirconium-89 (^89Zr). Its core utility is likely for immuno-PET, a modality used to non-invasively visualize and quantify biodistribution and target binding of biotherapeutics such as antibodies, antibody fragments, or related proteins[1]. The precise antigen or indication targeted by DFOPODSDAR2SC16-MB1 is not explicitly described in available literature, but naming conventions and the application of ^89Zr labeling suggest a primary use in research or early clinical imaging within oncology or immunotherapy drug development[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 89Zr-DFOPODSDAR2SC16-MB1.